7*24 Hotline：
Shenzhen xinlitai Pharmaceutical Co., Ltd. (002294)
Shenzhen xinlitai Pharmaceutical Co., Ltd. was established in 1998 and listed on Shenzhen Stock Exchange in 2009 (Stock Code: 002294). It is a comprehensive pharmaceutical listed company integrating R & D, production and sales of pharmaceutical products. Since 2013, xinlitai has been selected as the "top 20 competitive pharmaceutical listed companies in China" for many years, and in 2017 and 2018, xinlitai has been selected as the "top 10 pharmaceutical listed companies with R & D innovation in China" for two consecutive years.
With high-quality innovative products and evidence-based medicine promotion as the core competitiveness, while maintaining the leading position of cardiovascular and cerebrovascular high-end specialty drugs, xinlitai expands the target fields of hypoglycemic, anti-tumor, orthopedic and anti infection, rapidly enriches the product line and develops many heavy products through independent research and development, technical cooperation, investment and M & a.
The Research Institute of the group consists of chemical drug R & D, biological drug R & D and medical device R & D. It has a R & D team composed of nearly 1000 elites at home and abroad, with more than 100 projects under research.
The company's precise layout of the global industrial chain, business scope covers China, the United States, Germany, France, Japan and more than 30 countries and regions.
Xinlitai core product, anti platelet agglutination drug Taijia, passed the GMP certification of EU in 2012 and won the "Gold Award of Chinese patent" in 2016. In addition, the company has a number of independent intellectual property products, such as class 1 ARB antihypertensive new drug "xinlitan", chemical drug "teganin", etc.
Xinlitai always adheres to the concept of "beauty comes from integrity", adheres to the core value of "patient-centered", and devotes itself to human health with excellent pharmaceutical products.
oil wellhead